Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Altea Therapeutics
Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.
Plus deals involving ASLAN/Zenyaku Kogyo, AstraZeneca/Cholsegen, Astellas/Cullgen, AbCellera/Confo, Blue Water/WraSer, Solve/Cereius, Prime Medicine/Cimeio, Evox/Codiak, PharmaTher/Vitruvias and Adverum/Ray.
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.
- Controlled Release
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.